Boomtown

[ProfitScout]

$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com

"How NRx Could Upend the Fight Against Depression and Suicide"

RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.

The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:

"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
[e-mail]

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
[e-mail]

https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html

SOURCE NRx Pharmaceuticals, Inc.

[BlazingStocks]

$BHAT - Blue Hat Interactive Entertainment Technology Summary, Valuation, and Chart
https://www.marketscreener.com/quote/stock/BLUE-HAT-INTERACTIVE-ENTE-62745753/

[Value_Investor]

KXIN (NASDAQ-Exchange stock) is at Hyper Oversold status now --- from May 17's pre-market high $0.6 to last Friday's daily low $0.0745 which is 88% Huge price crash within just a few months!

Easy to surge back to $0.6 again based on its Huge Book Value --- $0.9842 a share!

Note, the 52-week-high is $5.5185 which is 9.2 Times of $0.6!

[BlazingStocks]

$BHAT - Originally an entertainment company, Blue Hat is now focusing on innovations in the commodity trading arena. The company is planning to integrate artificial intelligence to enhance its offerings, including an intelligent gold supply chain and recycling system, as well as a sophisticated gold derivatives trading platform.
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html

[Value_Investor]

AFFL just created a New 52-week-high $0.1 yesterday! The AS was diluted to 500M shares now from last June's 50M shares and the OS was diluted to 75.6M shares from 24.6M shares!

The 52-week-low is $0.0020!

[Value_Investor]

ASTI did Rapidly bounce to $5.29 from $2.7 after 1:100 Big R/S! A good NASDAQ stock to trade with!

[Alexulf]

t's HAPPENING! Gold & Silver to Blow Through the Roof -
with precious metals stock investor Peter Schiff

Two stocks to consider now; Euro Sun Mining https://www.barchart.com/stocks/quotes/ESM.TO/overview

and; https://www.barchart.com/stocks/quotes/BBBXF/overview

BOTH STOCKS ON OTC AND TSX

[Value_Investor]

PLUM seems bottomed out at $1.55. It had already bounced up over 77% most recently! Good chance to test $3 or above!

[Value_Investor]

TNXP has bounced Up 110.3% today after Good News --- from $0.4021 to $0.8456! Last January it did Quickly surge 5.2-Bagger to Pre-R/S's $1.456 from Pre-R/S's $0.28 --- see the first chart below!

This Hidden Gem is also at Hyper Oversold status --- from May 17's high $6.72 to Super-Ridiculous-Low $0.4021!

This Diamond_In_Rough has Shocking Huge Positive Book Value (BV) --- $1.92 a share!

So, TNXP is Super Undervalued now! Easy to surge over Pre-R/S's Bottom $3.84!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio 4.8!

There is a 4.5412-Bagger Huge Price-Gap between Pre-R/S's Bottom $3.84 and today's high $0.8456! So, we'll soon see a 5.2-Bagger+ Easy & Quick Rally again!

Note, the 200-Day MAL is at $8.00 from the second chart below!

Hopefully the company will issue some Very Good News to trigger the Upcoming 5.2-Bagger+ Huge Rally...

[Value_Investor]

KGRI will soon be Up-Listed to the Pink-Sheet Market just like its OTC peers (such as AFFL, BRLL, and MNGG etc.) did recently! This Hidden Gem had already reduced its AS to 560,000,000 shares from 5,000,000,000 shares! And the OS was reduced to 423,286,629 shares! The Diamond-In-Rough owns a Key CANNABIS-related US-Patent! The Highest-Trading-Volume (HTV) is measly 359,571,358 shares in its Entire trading history!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174287653

It will be Very Easy for KGRI to Quickly surge over its recent high 0.0015 and to create A Series Of New 52-Week Highs based on its peer's market value at their peaks!

Because buying its peer (BRLL: 382,837,825/450,000,000 shares OS/AS) at $3.00 = buying KGRI at $2.7134 which is 1809 Times of its recent high 0.0015!

Buying its peer (ITVI: 24,572,500,746/30,000,000,000 shares Giant OS/AS) at $0.0019 = buying KGRI at $0.1103 which is 74 Times of its recent high 0.0015!

Buying its peer (HPIL: 38,132,535,775/40,000,000,000 shares Giant OS/AS) at $0.0119 = buying KGRI at $1.0721 which is 715 Times of its recent high 0.0015!

Buying its peer (MNGG: 7,615,161,617/9,000,000,000 shares Huge OS/AS) at $0.0011 = buying KGRI at $0.0198 which is 13.2 Times of its recent high 0.0015!

Buying its peer (AFFL: 74,554,166/500,000,000 shares OS/AS) at $0.089 = buying KGRI at $0.01567 which is 10.5 Times of its recent high 0.0015!

So, KGRI is Super Undervalued now and it is Much-Much-Much-Much-Much Cheaper than BRLL, ITVI, HPIL, MNGG, AGBA, and AFFL etc. peers!

Note: HPIL and ITVI all have Billions shares of Huge HTV v.s. KGRI only has 0.3B shares of Tiny HTV!

[ProfitScout]

$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content

First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content

JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.

The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.

"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.

Key Findings:

Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.

Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."

For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.

About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.

About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com

Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html

SOURCE Safety Shot

[Zardiw]

$TENK +247%+ #DDAmanda Video Analysis - #1 Stock Scanner/Screener

Z

[Bansky]

$EBYH news out

https://finance.yahoo.com/news/strainsforpains-ebyh-ceo-simon-shainberg-100000188.html

What is the new partnership announced by Strainsforpains (EBYH)?
Strainsforpains (EBYH) has signed a strategic product commercialization agreement with Cannabis Science for international retail and wholesale cannabinoid drug distribution.

What are the projected sales for Strainsforpains (EBYH) in 2024?
Strainsforpains (EBYH) projects to surpass $500,000 in sales for 2024, based on recent orders and expanding partnerships.

What key products are included in the Strainsforpains (EBYH) and Cannabis Science partnership?
The partnership includes Cannabis Science's Harvard Award-winning cancer research and CBN patent for sleep and neurological disorders, as well as Strainsforpains' existing CBD product line.

How much in orders has Strainsforpains (EBYH) received recently?
Strainsforpains (EBYH) has received orders totaling $195,000, with $65,000 in Q4 2023 and $130,000 in early 2024.

[ProfitScout]

$NRXP News: HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff

Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff of 49% of HOPE Therapeutics shares to current NRx Shareholders has been denied by Utah arbitrator.

Petition by Streeterville Capital, LLC seeking injunctive relief to prevent sales of NRx shares has been denied by Utah arbitrator.

NRx to proceed with spinoff of HOPE Therapeutics as previously announced.

RADNOR, Pa., July 29, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced the issuance of an order by a Utah arbitrator denying the petition of Streeterville Capital, LLC to enjoin NRx's planned spinoff of 49% of the shares in HOPE Therapeutics to current shareholders of NRx pharmaceuticals. While the proposed spinoff remains subject to compliance with certain disclosure and other requirements under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, the spinoff is intended to provide NRx shareholders with an opportunity to participate in the anticipated value created as a result of the spinoff and to enable a potential listing of HOPE Therapeutics (currently a wholly-owned subsidiary of NRx) on a national securities exchange. The arbitrator also denied Streeterville's petition to enjoin NRx from selling additional shares of NRx stock to finance ongoing operations.

(PRNewsfoto/NRx Pharmaceuticals)

"As we have previously shared with the public, HOPE Therapeutics is in the process of developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression. This arbitration decision enables us to keep our promise to shareholders to spin out 49% of HOPE Therapeutics shares held by NRx to our shareholders, subject to approval by our Board of Directors and compliance with applicable law. We appreciate the support and loyalty of our shareholders as we work to bring HOPE to life," said Prof. Jonathan Javitt, Founder and Chairman of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-nasdaqnrxp-announce-arbitration-order-enabling-hope-therapeutics-spinoff-302208316.html

SOURCE NRx Pharmaceuticals, Inc.

[Alexulf]

Excellent entry point/refill - goldprice start moving up again - and so do the stock as well.
https://www.barchart.com/stocks/quotes/BBBXF/overview OTC
https://www.barchart.com/stocks/quotes/BBB.VN/overview TSX
Given goldprice climbing, silver resource awareness, high grade results from last update... things are moving!

https://brixtonmetals.com/

Maybe I´m wrong - still, I believe in a similar meltup as in 2016 this year/early 2025

[BlazingStocks]

$AGBA News July 05, 2024

AGBA Group, one of Nasdaq’s top 10 best-performing stocks for 2024, further cements strategic partnership with Yorkville
https://finance.yahoo.com/news/agba-group-one-nasdaq-top-130000537.html

[Golden Cross]

$IFUS GLP-1 Muscle Mass Loss Buoys the Protein Trade: INGR TSN ZTS IFUS
https://www.insiderfinancial.com/post/glp-1-muscle-mass-loss-buoys-the-protein-trade-ingr-tsn-zts-ifus

Other Mentions Stocks: $IGNR $ZTS $TSN $ADM $CALM $NATH $TSN $HRL $MDLZ $PEP $NOVO $LLY

[BlazingStocks]

$AGBA - Since going public via a SPAC in November 2023, AGBA's team of over 1,500+ employees has worked tirelessly everyday in delivering steady growth persistently quarter after quarter maintaining our market leadership.
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html

[Golden Cross]

$OCTO Undervalued here...

[BlazingStocks]

$AGBA - AGBA is making excellent progress in preparing its proxy statement regarding the proposed merger. AGBA expects to file its preliminary proxy statement with the SEC in early June 2024.
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore

[BlazingStocks]

$OCTO
The Company currently has approximately 8.8 million shares outstanding, resulting in a market capitalization of approximately $4.0 million based on the closing price of the Company’s common stock on June 28, 2024. Management believes the current market capitalization may not fully reflect the Company's substantial progress in enhancing shareholder equity and operational efficiencies described above.

[Golden Cross]

$EWRC News next week on current and future projects. Details on the upcoming release of their game, Last Seen; Last Night, on the Epic Games store (7/7). Steady accumulation here.

$EWRC’s press release next week will encompass current and future projects. It will also include our 1st person POV game schedule with a detailed roadmap with one of the gaming world’s premiere platforms.

— eWorld Companies, Inc (@eworld_company) June 28, 2024

[Value_Investor]

AFFL has $18.3515 Analyst's Target based on its Current-Information-tier peer's MV at its recent high $4.1! Once the Upcoming Reverse-Merger deal kicks in, this hidden gem (24,554,116 shares Tiny OS and 250M shares Tiny AS) will soar to $18.3515 in order to match the Same MV with SSHT (109,903,473 shares Large OS and 1B/1000M shares Huge AS) at its peak!

Note, the Analyst's Target $18.3515 = 206.2 Times of its recent high $0.089!

This CLEAN Shell has a Sought-After FIXED Tiny Shares-Structure and a Super-Positive Neat Financial Balance Sheet! It is easy to be Up-Listed to the NASDAQ Exchange after the Upcoming Reverse-Merger deal……

Buying its OTC-CI-tier peer (BDCC) at 52-week-high $27.747 = buying AFFL at $64.409 which is 2012.8 Times of Super-Ridiculous-Low 52-week-high $0.032!

Buying its OTC-CI-tier peer (BDCC) at current price $0.82 = buying AFFL at $1.9035 which is 67.3 Times of current Super-Ridiculous-Low price $0.0283!

Buying its OTC-CI-tier peer (BDCC) at 52-week-low $0.22 = buying AFFL at $0.5107 which is 255.4 Times of Super-Ridiculous-Low 52-week-low $0.002!

AFFL is Super Undervalued now --- Mere $694,881 MV at current Super-Ridiculous-Low price $0.0283 v.s. its Same CI-tier but Much-Worse peer is trading at Shocking-High $104,408,299 MV now!

AFFL is at Hyper Oversold status --- from its Record-High $6 to current Super-Ridiculous-Low price $0.0283!

In fact, AFFL ever hit a Historic-Record-High $6 with 67,801,926 shares of Old OS Count! But AFFL only has 24,554,116 shares of New OS Count now! So, it will create a New Historic-Record-High $16.568 in order to have the Same Market Value as before!

[BlazingStocks]

$SFWJ News June 12, 2024

SFWJ/MedCana Announces Strategic Partnership with Colombian Company to Begin Exporting CBD Buds to Switzerland
https://finance.yahoo.com/news/sfwj-medcana-announces-strategic-partnership-134500645.html

[ProfitScout]

$RENB Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy
Click here:
https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Amsterdam-UMC-Cancer-Center-Plan-to-Form-Joint-Venture-for-Cancer-Immunotherapy-46820158/ @Nasdaq @Marketscreener1 #collaboration

[Alexulf]

ESM Responds to EU Commission Call For Strategic Mining Projects!

https://ceo.ca/@globenewswire/euro-sun-mining-responds-to-european-commission-call

Part of article;

ESM wishes to confirm that the Company has formally begun proceedings to list its Rovina Valley Project (the “Project”)
with the European Commission as a “strategic project” for the European supply of critical minerals.

Following a meeting held on May 27, 2024 with the Romanian Ministry of Economy, the application for the Project to be
designated as a “strategic project” within the European Commission’s Critical Raw Materials Act was sanctioned.

This positive development will take place whilst Romania continues towards overhauling its
existing mining legislation to align with the Critical Raw Materials Act.

IMO very important news, yet the market do not react (so far?), with a gain in the share price - maybe a delayed effect will play out.

With the project officially supported by the EU commision, the Romanian side will also play ball - no more stalling -
cause now it`s in the interest of the new government to succeed with it, not only the company itself -
the CEO`s 4% stake of OS is also a significant fact that will pay of to shareholders.

BULLISH

[BlazingStocks]

$BDCC - A product of prestigious universities, Mohammed's academic background in Civil Engineering serves as the bedrock of his illustrious career, providing him with the technical proficiency and strategic insight necessary to navigate the complexities of the industry with unparalleled finesse.
https://finance.yahoo.com/news/blackwell-3d-corporation-secures-services-040533630.html

[BlazingStocks]

$AGBA News May 21, 2024

AGBA/Triller $4bn Merger: Excellent Progress Ahead of Plan
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore

[ProfitScout]

$SHOT: Safety Shot Partners with Capital Drugs To Launch World's First Beverage To Reduce Blood Alcohol Content in 300 Pharmacies Across the Country

The First of its Kind Vitamin-Packed, Wellness Beverage Brand Continues to Amplify its In-Store Availability Nationwide

JUPITER, Fla., June 6, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company), announced today its partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.

Entering a key market for Safety Shot consumers, Capital Drugs is known for providing a wide range of pharmaceutical services and products tailored to specific health and wellness needs. Capital Drugs offers traditional pharmacy and clinical services in tandem with alternative medicine options such as supplements, vitamins, and homeopathic products.

"Entering Capital Drugs pharmacies is an integral next step in furthering Safety Shots key messaging and purpose of operating as a functional wellness beverage," said Josh Wagner, Chief Revenue Officer at Safety Shot. "Expanding on-shelf availability and having the product available for purchase in key locations like Capital Drug pharmacies is the brand's core mission, introducing the first-of-its-kind beverage to a like-minded consumer audience."

This latest affiliation aligns with the brand's comprehensive nationwide availability rollout and partnership expansion plan. This announcement comes on the heels of its Northeast expansion across New York and New Jersey through boutique broker Prime CBS and additional partnerships with GoPuff, BevMo and more.

About Safety Shot, Inc

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

SOURCE Safety Shot

[Value_Investor]

ASTI did Rapidly surge to $0.203 from $0.1131 on June 3! However, it crashed down to $0.095 today! So, it may Quickly bounce up to test $0.2xxx again as soon as the coming week...

ASTI is currently at Extremely Oversold status --- from its most Recent high $0.34 (on May 23) to current Ridiculous-Low price levels $0.09xx!

[Value_Investor]

TTNXP was Up over 21% in After-Hour session on June 13 after Good News (see the link below)! Last January it did Quickly surge 5.2-Bagger to Pre-R/S's $1.456 from Pre-R/S's $0.28 --- see the first chart below!

https://www.otcmarkets.com/filing/html?id=17619193&guid=cqQ-kamb8r4T4rh

This Hidden Gem is also at Hyper Oversold status --- from May 17's high $6.72 to June 13's Super-Ridiculous-Low price $1.08!

This Diamond_In_Rough has Shocking Huge Positive Book Value (BV) --- $36.22 a share which is 33.54 Times of Super-Ridiculous-Low price $1.08! Also it has Huge Positive Cash Value --- $2.36 a share which is 2.19 Times of Super-Ridiculous-Low price $1.08!

That means that TNXP is Super Undervalued now! Easy to surge over May 17's high $6.72!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

There is a 3.2-Bagger Huge Price-Gap between $3.84 and June 12's high $1.2! So, we'll soon see a 5.2-Bagger+ Easy & Quick Rally again!

Note, the 50-Day MAL is at $5.13 from the second chart below!

Hopefully as soon as next week the company will issue some Very Good News to trigger the Upcoming 5.2-Bagger+ Huge Rally...

[BlazingStocks]

$AGBA News June 12, 2024

AGBA/Triller $4bn Merger: The Group files its Preliminary Proxy Statement
https://finance.yahoo.com/news/agba-triller-4bn-merger-group-122000311.html

[BlazingStocks]

$FAVO News June 11, 2024

FAVO Capital, Inc. Appoints Turner, Stone & Company, LLP as Auditors
https://finance.yahoo.com/news/favo-capital-inc-appoints-turner-171500774.html

[Alexulf]

PlantX Life - Certain things taking place lately, makes me for now to be more carefull, I do simply need to check in to new developments/troubles?

So, it`s a HOLD from my side - do your own research on all parts of PlantX.

[BlazingStocks]

$AGBA - Triller now fully focuses on pooling its resources and attention towards completing the proposed merger with AGBA within a short timetable.
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore

[BlazingStocks]

$FAVO - This accolade celebrates Stewards Investment Capital's instrumental role in facilitating the ground-breaking acquisition of FAVO Capital, resulting in FAVO Capital's acquisition of all entities forming the FAVO Group of Companies.
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-171000225.html

[ProfitScout]

$GV News: Broader Development Opportunities for PSW Sector

TORONTO, June 7, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the cooperation with Canadian International Career College (CICC) will have broader development opportunities.

On June 3, 2024 the Honourable Marc Miller, Minister of Immigration, Refugees and Citizenship announced two pilot programs that allow caregivers to directly obtain PR status upon arrival in Canada.

The new pilot programs require caregivers to have a full-time job offer for a home care position, relevant work experience, a language proficiency of CLB (Canadian Language Benchmarks) level 4, and an education level equivalent to a Canadian high school diploma. These new pilot programs expedite the immigration process for caregivers coming to Canada to care for children, the elderly, and people with disabilities. Caregivers can also work for organizations that provide temporary or part-time care services to individuals who are semi-independent or recovering from injuries. This new pathway means that caregivers can more easily find employers.

This news is extremely beneficial for the PSW (Personal Support Worker) industry. the Company's subordinate Farvision Career Education Group Inc signed a cooperation agreement with Canadian International Career College to explore the market in Asia on May 9,2024. We believe with the implementation of the two pilot programs in Canada, we will have more support for our development in the Asian market. The company will expedite its efforts to develop the Asian market.

The Canadian International Career College (CICC) provides Personal Support Worker Certificate, Medication Administration for PSW Certificate Course, Early Childcare Assistant (ECA) Diploma Course, Intensive Care Unit (ICU) Program for Nurse Certificate Course, Medical Surgical Certificate Course, CPR/AED Certificate Course, Standard First Aid with CPR Course, and Business Programs.

About Visionary Holdings Inc.

Visionary Holdings Inc. headquartered in Toronto, Canada, is a private education provider located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
Email: [e-mail]



https://c212.net/c/img/favicon.png?sn=CN34236&sd=2024-06-07 View original content:https://www.prnewswire.com/news-releases/broader-development-opportunities-for-psw-sector-302167022.html

SOURCE Visionary Holdings Inc.

[Value_Investor]

BRLL has 450M shares Large AS and 382,837,825 shares Huge OS but it ever hit $3 recently with Very Ridiculous High MV ($13,399,324 ~ $1,339,932) based on its 52-week price range of $0.0035 ~ $0.035 v.s. its Much-Much-Much-Smaller-SS peer AFFL only has 250M shares Tiny AS and 24,554,116 shares Super Tiny OS but it is trading at Super Ridiculous Low price levels $0.0295 ~ $0.02 most recently with Super Ridiculous Low MV ($724,346 ~ $49,108) based on its 52-week price range of $0.0020 ~ $0.0295!

Buying BRLL at its recent high $3.00 = buying AFFL at $46.7748 which is 1586 Times of its current super ridiculous low 52-week-high $0.0295!

Buying BRLL at its 52-week-high $0.035 = buying AFFL at $0.5457 which is 18.5 Times of its current super ridiculous low 52-week-high $0.0295!

Buying BRLL at its 52-week-low $0.0035 = buying AFFL at $0.0546 which is 27.3 Times of its current super ridiculous low 52-week-low $0.0020!

BRLL has -$6,090,794 Huge Negative Net Asset v.s. AFFL only has -$26,445 minor negative Net Asset!

[ProfitScout]

$GV News: Top Reasons to Have GV on Your Radar

TORONTO, June 4, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the top reasons to have GV stocks.

Strategic Transition: In response to changing education policies, GV strategically transitioned from traditional education to high technology, life sciences, and AI education, positioning itself at the forefront of innovation.

Diversification of Revenue Streams: With a focus on high-tech and AI education, GV expanded its revenue streams beyond traditional education, tapping into lucrative markets in technology, life sciences, and artificial intelligence.

Expansion into New Markets: Through collaborations with global partners, GV expanded its market presence beyond Canada, leveraging its expertise in education technology to tap into international markets.

Innovative Education Programs: GV introduced innovative education programs, including the Algoma University Learners Early Access Program (LEAP), offering students unique pathways to postsecondary education and fostering international collaboration.

Strong Leadership: Under the guidance of experienced leadership, including CEO Mr. Zhong Chen, GV has executed strategic initiatives effectively, driving growth and innovation in the high technology, life sciences, and AI education.

Global Collaborations: Our strategic alliances with industry leaders such as Red Sun Group and Shenzhen Guoli Intelligent Technology Group amplify our reach and capabilities. These partnerships facilitate groundbreaking initiatives in life sciences, AI education, and STEM, driving innovation and value creation.

Cutting-Edge Biochip Technology: With our partnership with Canada BRAUN Bio Technology Group Inc., Visionary is at the forefront of biochip technology. Our world-class products address critical needs in medical testing, drug development, and more, positioning us as leaders in Canada's burgeoning biotech sector.

New Energy Vehicles: Visionary Group, is having intention to collaborate with Farnova Holding Group, which will be Canada's first independent brand of new energy vehicles. This initiative addresses a critical need in the market and promotes eco-conscious transportation solutions.

About Visionary Holdings Inc.

Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
Email: [e-mail]

https://c212.net/c/img/favicon.png?sn=CN30587&sd=2024-06-04 View original content:https://www.prnewswire.com/news-releases/top-reasons-to-have-gv-on-your-radar-302162725.html

SOURCE Visionary Holdings Inc.

[ProfitScout]

$AVRW News: Avenir Wellness Solutions Reports Fourth Quarter 2023 Results

New Initiatives Showing Encouraging Results

SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2024 / Avenir Wellness Solutions, Inc. (OTCQB:AVRW) ("Avenir" or the "Company" , a proprietary broad platform technology and wellness company, today announced results for the fourth fiscal quarter ended December 30, 2023.

Key financial highlights for the fourth quarter included the following:

Net revenue in the fourth quarter of 2023 increased to $1.1 million from the same period in 2022 by $0.2 million, or 11.7%, and also increased sequentially from Q3 2023 by $43 thousand, or 4.4%. Overall growth was lower than expected due to the continued delay in receiving the expected remainder of the asset sale proceeds to be used for advertising and marketing to drive sales. The quarter did, however, benefit from a new relationship with leading online and beauty subscription box retailer, FabFitFun.

Gross margin increased 407 basis points year over year in the fourth quarter of 2023 due to improved working capital management offset in part by a higher proportion of sales coming from our wholesale channel of distribution with its lower margins than our higher-margin direct-to-consumer sales channel.

Gross margin for the third quarter of 2023 decreased sequentially from the second quarter of 2023 by 26 basis points due to a shift in sales channel mix with a higher proportion of wholesale sales to Amazon and FabFitFun which resulted in shipments of approximately $0.3 million.

Cost containment initiatives led to a favorable impact on SG&A expenses (excluding non-cash charges) for the fourth quarter with a decrease of $357 thousand in 2023 compared to 2022 driven by decreased spend on advertising and promotion of $325 thousand lower overhead by $32 thousand.

Net operating loss from continuing operations (excluding non-cash charges) improved by $0.9 million in 2023.

"Our products continue to maintain sales levels which is encouraging given that we have been unable to fully execute on our marketing initiatives pending receipt of the balance of the proceeds from the July 2022 asset sale. As mentioned in our third quarter earnings announcement, the proceeds from the July 2022 asset sale allow us to invest in the future of the Company, but the delay in receiving the balance of the proceeds continued to have an impact on our operating performance. We expect accelerating sales will reaffirm the improving overall trajectory of the business. Further, our margin expansion initiatives continue to deliver results with improvement from third quarter, and we continue our overall cost containment initiatives to further reduce SG&A expenses and to maximize operating leverage.

Fine tuning our Search Engine Optimization (SEO), bringing our media buying in house and achieving successful monthly campaigns like theSkimm continue to deliver for us as we execute on our strategy to build our brands," said Nancy Duitch, Avenir CEO.

Operational Highlights

Other operational highlights during the fourth quarter of 2023 included:

Our newly formulated Seratopical Revolution Cracked Heel Souffle was selected for inclusion in FatFitFun's Summer 2024 subscription box selling out an astonishing 80,000 units in under 43 minutes. Click link to view Instagram videos on our Cracked Heel Souffle.
Our DNA Complex hero product continues to perform as our subscription based grows.
Wholesale sales led by Amazon continue to grow with all the positive product reviews.
We began development of our new TikTok shop to capitalize on the evolving digital ecommerce landscape which launched in the second quarter of 2024.
For further details, please visit our website to review our most recent Form 10-K filed on May 17, 2024 at: http://www.avenirwellness.com/sec-filings/

About Avenir Wellness Solutions, Inc.

Avenir Wellness Solutions, Inc. (OTCQB:AVRW) is a broad platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems which are integrated into our wellness and beauty products and sold directly to the consumer. The technology, which is based on (15) fifteen current patents, offers a number of unique immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The Company will continue down the path of creating new technologies that is part of its incubator strategy in order to monetize its intellectual property as well as expand our product lines utilizing the technology. As a vertically integrated platform company, Avenir looks to partner or license its IP technology with wellness companies worldwide. For more information visit: http://www.avenirwellness.com.

About The Sera Labs, Inc.

Sera Labs, a wholly owned subsidiary of Avenir, is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting-edge technology. Sera Labs creates high-quality products that use science-backed, proprietary formulations. More than 25 products are sold under the brand names Seratopical™, Seratopical Revolution™, SeraLabs™, and Nutri-Strips™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health and wellness, Sera Labs products are sold direct-to-consumer (DTC) via online website orders, including a subscribe and save option, and also sold online and in-store at major national drug, grocery chains, convenience stores, and mass retailers and on Amazon.com. For more information visit: www.seralabshealth.com and follow Sera Labs on Facebook, Instagram and TikTok at @seratopical as well as on X (Twitter) at @sera_labs.

Forward Looking Statement

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including statements regarding the future growth and success of our organization. We have attempted to identify forward-looking statements by using words such as "anticipate," "believe," "could," "estimate," "expected," "intend," "may," "plan," "predict," "project," "should," "will," or "would," and similar expressions or the negative of these expressions.

Forward-looking statements represent our management's current expectations and predictions about trends affecting our business and industry and are based on information available as of the time such statements are made. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy or completeness. Forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements predicted, assumed or implied by the forward-looking statements. Some of the risks and uncertainties that may cause our actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by applicable law, we expressly disclaim any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in our expectations, or as a result of the availability of new information.

CONTACTS:

Investor Relations
Hanover International Inc.
T: [phone]
E: [e-mail]

SOURCE: Avenir Wellness Solutions, Inc. (f/k/a Cure Pharmaceutical Holding Corp.)

[Value_Investor]

SSHT has 1B shares Huge AS and 109,903,473 shares Large OS but it ever hit $4.1 recently with super ridiculous high 52-week price range of $0.2951 ~ $1.16 v.s. its Much-Much-Much-Smaller-SS peer AFFL only has 250M shares Tiny AS and 24,554,116 shares Super Tiny OS but it is trading at super ridiculous low price levels $0.0295 ~ $0.02 most recently with super ridiculous low 52-week price range of $0.0020 ~ $0.0295!

Buying SSHT at $4.1 = buying AFFL at $18.51 which is 712 Times of its current ridiculous low price $0.026!

Buying SSHT at $0.2951 = buying AFFL at $1.3209 which is 51 Times of its current ridiculous low price $0.026!

SSHT has -$54,256 Net Asset v.s. AFFL has -$26,445 Net Asset!

[BlazingStocks]

$FAVO - recognized by Global Finance for the Best Fixed Income Investment Innovation Award as part of their Annual Top Innovation in Finance Awards for 2024.
https://finance.yahoo.com/news/favo-capital-stewards-investment-capital-130500781.html

[ProfitScout]

$GV News: GV Announces Cooperation with CICC

TORONTO, May 22, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the Company's subordinate Farvision Career Education Group Inc signed a cooperation agreement with Canadian International Career College to explore the market in Asia on May 9,2024.

As Canada's aging population continues to rise, the government has implemented various measures to address the issue by attracting foreign workers to the PSWs sector. According to the Canadian Association of Senior Housing and Care Providers, the healthcare sector contributes over CA$100 billion to the Canadian economy each year.

The shortage of labor has resulted in a critical need for foreign workers in the personal support worker (PSW) field to fill the workforce gap and provide essential care and support to seniors and individuals with disabilities.

In addition to the economic benefits, the influx of foreign labor as PSWs also has a positive impact on the Canadian healthcare system. PSWs often serve as the primary caregivers for seniors and individuals with disabilities, playing a crucial role in assisting them with daily activities and maintaining their independence.

The courses offered by the Canadian International Career College (CICC) include Personal Support Worker Certificate, Medication Administration for PSW Certificate Course, Early Childcare Assistant (ECA) Diploma Course, Intensive Care Unit (ICU) Program for Nurse Certificate Course, Medical Surgical Certificate Course, CPR/AED Certificate Course, Standard First Aid with CPR Course, and Business Programs.

After completing all courses and passing exams, Farvision Career Education Group and CICC will assist students in obtaining work visas and provide job referrals. For local Chinese students, they can complete remote courses in China and receive certificates recognized by both China and the province of Ontario, Canada, upon passing exams.

This project will bring a new revenue growth point to the Company.

About Visionary Holdings Inc.

Visionary Holdings Inc. headquartered in Toronto, Canada, a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

For more information, please contact:

Visionary Holdings Inc.
Investor Relations Department
[e-mail]

Cision View original content:https://www.prnewswire.com/news-releases/gv-announces-cooperation-with-cicc-302152260.html

SOURCE Visionary Holdings Inc.

[Value_Investor]

KXIN (NASDAQ-Exchange stock) is at Hyper Oversold status now --- from May 17's pre-market high $0.6 to last Friday's daily low $0.15 which is 75% price crashing within just a week!

Easy to surge back to $0.6 again within just a couple of days just like it did a week ago...

Note, the 52-week-high is $6.6 which is 11 Times of $0.6!

[Zardiw]

$CATV Trading at 1/2 of Book Value.....

Z

[Alexulf]

ES Mining successfull meeting with Ministry of Economy (December 2023) and the Romanian Ministry of Environment, Water, and Forests (January 2024).

https://www.theglobeandmail.com/investing/mar.../research/

https://www.eurosunmining.com/wp-content/uplo...un-PPT.pdf

[BlazingStocks]

$AGBA Squeeze coming. Triller $4bn Merger Update this week, Excellent Progress Ahead of Plan.

Expecting more updates really soon.

https://www.reddit.com/r/Shortsqueeze/s/gv7mTzj0Og

[Value_Investor]

AFFL has $18.51 Analyst's Target based on its OTC peer's MV at its most recent high $4.1! Once the Upcoming Reverse-Merger deal kicks in, this hidden gem (24,354,116 shares Tiny OS and 250M shares Tiny AS) will soar to $18.51 in order to match the Same MV with SSHT (109,903,473 shares Large OS and 1B/1000M shares Huge AS) at its peak!

Note, the Analyst's Target $18.51 is equal to 208 Times of its recent high $0.089!

This CLEAN Shell has a Sought-After FIXED Tiny Shares Structure and a Super-Positive Neat Financial Balance Sheet! It is easy to be Up-Listed to the NASDAQ Exchange after the Upcoming Reverse-Merger deal……

AFFL is Super Undervalued now --- mere $367,747.15 MV at current ridiculous low price $0.0151 v.s. its peer did hit $450,604,239.30 MV most recently!

AFFL is at Hyper Oversold status --- from its recent high $0.089 to current Super ridiculous low 52-week-low $0.0020!

[Alexulf]

UP X 2 Or DOUBLE right now, see the PlantX board, as this is only the beginning.

https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643

[ProfitScout]

$GRLF: Green Leaf Innovations, Inc. Sets Sail for History

Join Cubanacan Heritage at Battleship New Jersey Museum's Annual 'Cigars on the River' Event

PEMBROKE PINES, FL / ACCESSWIRE / May 15, 2024 / Green Leaf Innovations, Inc., (OTC PINK:GRLF), an importer and wholesale distributor of premium hand-rolled cigars, is proud to announce its participation in the highly anticipated 'Cigars on the River' event at the iconic Battleship New Jersey Museum and Memorial.

Overlooking the majestic Delaware River and the breathtaking Philadelphia skyline, this annual soirée promises an unforgettable evening of indulgence and philanthropy. Guests will savor the finest cigars, exquisite cuisine, and handcrafted cocktails amidst the historic setting of the Battleship New Jersey.

Cubanacan Heritage, a cornerstone of Green Leaf Innovations, Inc.'s esteemed portfolio, will take center stage at this prestigious event, showcasing the rich heritage and unrivaled craftsmanship behind each meticulously hand-rolled cigar.

About Battleship New Jersey Museum and Memorial: The Battleship New Jersey Museum and Memorial stands as a testament to our nation's military prowess and enduring legacy. From its storied past in World War II to its pivotal role in modern naval history, the battleship offers a captivating glimpse into the triumphs and sacrifices of our armed forces. Immerse yourself in a journey through time and honor the heroes who have served our country with courage and valor.

Don't miss this exclusive opportunity to join Green Leaf Innovations, Inc. and Cubanacan Heritage aboard the Battleship New Jersey for an evening of camaraderie, celebration, and support for a noble cause.

About Green Leaf Innovations, Inc.

Green Leaf Innovations, Inc., a Florida corporation, is an emerging growth company engaged in the Marketing and Distribution of handmade premium cigars. The company strategically imports and exclusively distributes some of the best known premium cigar brands in the Market created by the Mederos family a Third generation Cigar maker with Robert Mederos at the helm who has owned and operated handmade cigar operation in Nicaragua and the US for over 20 years with a rich family history in the craft dating back to the 1800s Cuba, brands such as CUBANACAN, MEDEROS and TABACALERA SERRANO. In addition to it the company also distributes packaged whole leaf Tobacco to cigar lounges, smoke shops, C-stores and vape shops across the United States and soon International Markets.

Additional information can be found on our websites http://www.greenleafinnovation.com or follow us on Twitter @otcgrlf.

For more information, press only:

PR Contact Name: Ryan Medico
Phone number: [phone]
Email: [e-mail]

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.

SOURCE: Green Leaf Innovations, Inc.